The 8 ingredients to biopharma R&D productivity

As biopharmaceutical R&D organizations face pressure to boost productivity, pharma leaders are turning to advanced technologies to reshape operations and deliver new efficiencies. Leading companies are already reaping benefits from well-designed tech stacks, but the industry’s overall R&D productivity has been mostly flat, write McKinsey’s Jeffrey Lewis and Joachim Bleys.

For eight ingredients to achieve sustained performance growth, explore “RewiR&D: Making more medicines that matter,” a special collection of recently published articles that offer practical solutions to biopharmaceutical innovation challenges. Together, these articles provide a recipe to boost R&D productivity and accelerate the development of lifesaving therapies.

Boosting biopharma R&D performance with a next-generation technology stack

Operational excellence in biopharma research and early development

Unlocking peak operational performance in clinical development with artificial intelligence

Strengthening the R&D operating model for pharmaceutical companies

External innovation: Biopharma dealmaking to boost R&D productivity